PMID- 38228941
OWN - NLM
STAT- MEDLINE
DCOM- 20240509
LR  - 20240509
IS  - 1590-3478 (Electronic)
IS  - 1590-1874 (Linking)
VI  - 45
IP  - 6
DP  - 2024 Jun
TI  - Symptoms and age of prodromal Alzheimer's disease in Down syndrome: a systematic 
      review and meta-analysis.
PG  - 2445-2460
LID - 10.1007/s10072-023-07292-9 [doi]
AB  - The diagnostic criteria for adult-onset Alzheimer's disease (AD) in patients with 
      Down syndrome (DS) have not been standardised. This study investigated the 
      specific symptoms of AD in the prodromal stage of DS, the mean age at diagnosis 
      at each stage of dementia, and the relationship between intellectual disability 
      (ID) and dementia. PubMed, Web of Science, and Embase were searched for studies 
      on DS, AD, early-stage disease, initial symptoms, and prodromal dementia 
      registered between January 2012 and January 2022. We also performed a 
      meta-analysis of the differences between the mean age at prodromal symptoms and 
      AD diagnosis and the proportion of mild cognitive impairment in patients with 
      mild and moderately abnormal ID. We selected 14 articles reporting the 
      behavioural and psychological symptoms of dementia (BPSD) and memory- and 
      language-related impairments as early symptoms of AD in patients with DS. The 
      specific symptoms of BPSD were classified into five categories: irritability 
      (agitation), apathy, abnormal behaviour, adaptive functioning, and sleep 
      disturbance. The mean age at the diagnosis of prodromal symptoms and AD dementia 
      was 52.7 and 56.2 years, respectively (mean difference, + 3.11 years; 95% CI 
      1.82-4.40) in the meta-analysis. The diagnosis of mild dementia tended to 
      correlate with ID severity (odds ratio [OR], 1.38; 95% CI 0.87-2.18). The 
      features of behaviour-variant frontotemporal dementia may be clinically confirmed 
      in diagnosing early symptoms of DS-associated AD (DSAD). Moreover, 
      age-appropriate cognitive assessment is important. Further studies are required 
      to evaluate DSAD using a combination of biomarkers and ID-related data.
CI  - (c) 2024. Fondazione Societa Italiana di Neurologia.
FAU - Shimizu, Eri
AU  - Shimizu E
AD  - Department of Clinical Genetics, Juntendo University, 2-1-1, Hongo, Bunkyo-Ku, 
      Tokyo, 113-8421, Japan.
FAU - Goto-Hirano, Keiko
AU  - Goto-Hirano K
AUID- ORCID: 0000-0001-6684-3332
AD  - Department of Clinical Genetics, Juntendo University, 2-1-1, Hongo, Bunkyo-Ku, 
      Tokyo, 113-8421, Japan. khirano@juntendo.ac.jp.
FAU - Motoi, Yumiko
AU  - Motoi Y
AD  - The Medical Center for Dementia, Juntendo Hospital, Tokyo, Japan.
FAU - Arai, Masami
AU  - Arai M
AD  - Department of Clinical Genetics, Juntendo University, 2-1-1, Hongo, Bunkyo-Ku, 
      Tokyo, 113-8421, Japan.
FAU - Hattori, Nobutaka
AU  - Hattori N
AD  - Department of Neurology, Juntendo University, Tokyo, Japan.
LA  - eng
GR  - JP23K08279/Japan Society for the Promotion of Science/
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20240116
PL  - Italy
TA  - Neurol Sci
JT  - Neurological sciences : official journal of the Italian Neurological Society and 
      of the Italian Society of Clinical Neurophysiology
JID - 100959175
SB  - IM
MH  - *Down Syndrome/complications
MH  - Humans
MH  - *Alzheimer Disease/diagnosis/complications
MH  - *Prodromal Symptoms
MH  - Cognitive Dysfunction/etiology/diagnosis
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - BPSD
OT  - Down syndrome
OT  - Prodromal symptoms
EDAT- 2024/01/17 00:42
MHDA- 2024/05/10 00:42
CRDT- 2024/01/16 23:31
PHST- 2023/07/20 00:00 [received]
PHST- 2023/12/22 00:00 [accepted]
PHST- 2024/05/10 00:42 [medline]
PHST- 2024/01/17 00:42 [pubmed]
PHST- 2024/01/16 23:31 [entrez]
AID - 10.1007/s10072-023-07292-9 [pii]
AID - 10.1007/s10072-023-07292-9 [doi]
PST - ppublish
SO  - Neurol Sci. 2024 Jun;45(6):2445-2460. doi: 10.1007/s10072-023-07292-9. Epub 2024 
      Jan 16.